Immunology News and Research

Latest Immunology News and Research

Idera second quarter net loss increases to $6.3 million

Idera Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like receptors (TLRs).

5 Aug 2011

New strategies for successful donor adult stem cell transplants in blood cancer patients

Findings by UT Southwestern Medical Center researchers may suggest new strategies for successful donor adult stem cell transplants in patients with blood cancers such as leukemia, lymphoma and myeloma.

5 Aug 2011

Entomologist to study how immune system responds to rickettsial infection

Summer for most people means time spent outdoors, which could also mean increased exposure to bugs and, possibly, arthropod-borne diseases, such as "rickettsial diseases" - infectious diseases spread by bacteria, which, generally, are transmitted by lice, fleas, ticks and mites.

5 Aug 2011

BD Biosciences, Fluidigm to co-host public seminars on isolation and analysis of single cells

Fluidigm Corporation announced today a collaboration with BD Biosciences, a segment of BD, to co-host a public seminar series on the isolation and analysis of single cells. Entitled A Powerful Technique for Single-Cell Analysis, the public seminar series will showcase cell isolation using the BD FACSAria III Cell Sorter and analysis using the Fluidigm BioMark HD System.

From BD (Becton, Dickinson and Company) 5 Aug 2011

Novel DNA sensing pathway linked to increased susceptibility to malaria

Scientists at the University of Massachusetts Medical School have uncovered a novel DNA-sensing pathway important to the triggering of an innate immune response for malaria. Activation of this pathway appears to stimulate production of an overabundance of type-1 interferon by the immune system that may contribute to inflammation and fever in malaria patients and could play a part in susceptibility for the most common and lethal form of malaria known as plasmodium falciparum.

5 Aug 2011

Higher levels of B cells make women more prone to autoimmune diseases

Researchers at National Jewish Health have discovered a type of cell that may contribute to autoimmune disease and suggests why diseases such as lupus, multiple sclerosis and rheumatoid arthritis strike women more frequently than men. The cells, a subset of immune-system B cells, make autoantibodies, which bind to and attack the body's own tissue.

5 Aug 2011

Study: Poorly controlled asthma doubles healthcare costs linked with disease

Poorly controlled asthma more than doubles healthcare costs associated with the disease and threatens educational achievement through a dramatic increase in school absence, according to researchers at National Jewish Health.

5 Aug 2011

Virginia Tech student receives prestigious award for cellular signaling receptor study linked to diabetes, obesity

Stephanie Nicole "Nikki" Lewis, a graduate student in the interdisciplinary doctoral program in genetics, bioinformatics, and computational biology at Virginia Tech, has been awarded the prestigious Ruth L. Kirschstein National Research Service Award for Predoctoral Research through the National Institutes of Health for her study of a cellular signaling receptor that is associated with chronic inflammatory diseases such as diabetes, obesity, and inflammatory bowel disease.

5 Aug 2011

Biotica acquires full rights to rapamycin analogue program from Pfizer

Biotica Technology Ltd. today announced that it has regained full rights from Pfizer Inc. to its rapamycin analogue program, including transfer of data and materials.

3 Aug 2011

Needle-free nanopatch vaccine delivery system

The needle-free nanopatch vaccine delivery system is coming soon after a consortium of investors put up $15 million for its development. The money will enable University of Queensland's Professor Mark Kendall to continue his work on the technology. It is described as the biggest breakthrough in vaccine delivery since the invention of the syringe more than 150 years ago.

3 Aug 2011

Compugen second quarter net income increases to $1.2 million

Compugen Ltd. today reported its results for the second quarter ending June 30, 2011.

2 Aug 2011

Lack of TLR1 surface expression linked with increased susceptibility to tuberculosis

Are you genetically predisposed to tuberculosis? Scientists may now be able to answer this question and doctors may be able to adjust their therapeutic approach based on what they learn. That's because new research presented in the Journal of Leukocyte Biology suggests that two frequent mutations in an immune system gene called TLR1 are responsible for cellular changes that ultimately make us less likely to resist the disease.

2 Aug 2011

Early life exposure to mold may increase risk of asthma in infants

Infants who live in "moldy" homes are three times more likely to develop asthma by age 7—an age that children can be accurately diagnosed with the condition.

2 Aug 2011

RSS honors UNC researcher with 2011 Distinguished Service to Rural Life Award

Joanne M. Jordan, MD, MPH, director of the Thurston Arthritis Research Center at the University of North Carolina at Chapel Hill, has received the 2011 Distinguished Service to Rural Life Award from the Rural Sociological Society.

2 Aug 2011

Universal flu vaccine based on “super antibody” coming soon

Researchers have finally found the first antibody which can fight all types of the influenza A virus. The results of the experiments on flu-infected mice, published in Science Express, showed the antibody could be used as an “emergency treatment” for flu as well.

31 Jul 2011

Skin cancer vaccine on the way: Cancer expert Prof Ian Frazer

In a major medical breakthrough, cancer expert Prof Ian Frazer is on the verge of developing a vaccine against skin cancer within a year. The former ‘Australian of the Year’ and creator of the world's first cervical cancer vaccine, Gardasil, has developed a world-first strategy to combat the insidious disease that affects two out of three Australians.

31 Jul 2011

ORENCIA SC formulation receives FDA approval for treatment of adults with RA

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved a subcutaneous formulation of ORENCIA (abatacept) for the treatment of adults with moderate to severe rheumatoid arthritis.

30 Jul 2011

WSU professor receives NIH grant for non-alcoholic fatty liver disease research

Kezhong Zhang, Ph.D., assistant professor of molecular medicine and genetics and of immunology and microbiology in the School of Medicine at Wayne State University, was awarded $1.7 million by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health to explore how molecular elements in the body regulate the development of non-alcoholic fatty liver disease.

29 Jul 2011

Sigma-Tau, Soligenix expand partnership to develop and commercialize orBec in Europe

Soligenix, Inc., a late-stage biopharmaceutical company, announces the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization of orBec into the European territory.

29 Jul 2011

Universal flu vaccine with super antibodies in near future

Researchers are close to developing a “super antibody” against flu that could be used as a universal treatment and pave the way for the development of a universal vaccine against the disease that affects billions of people every year.

29 Jul 2011